GLYDO (lidocaine hydrochloride) by Sagent Pharmaceuticals is impulses, thereby effecting local anesthetic action. Approved for control of pain in procedures involving the male, female urethra () for topical treatment of painful urethritis (), nasal endotracheal intubation (). First approved in 2014.
Drug data last refreshed 3h ago
impulses, thereby effecting local anesthetic action.
Worked on GLYDO at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo